

Association Between Amplification and Expression of C-MYC Gene and Clinicopathological Characteristics of Stomach Cancer

Malihea Khaleghian,¹ Issa Jahanzad,² Abbas Shakoori,¹ Amirnader Emami Razavi,³ and Cyrus Azimi^{1,*}

¹Department of Medical Genetics, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IR Iran

²Department of Pathology, Immunohistochemistry Laboratory, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IR Iran

³Department of Pathology, Iran National Tumor Bank, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IR Iran

*Corresponding Author: Cyrus Azimi, Department of Medical Genetics, Cancer Institute of Iran, Tehran University of Medical Sciences, P. O. Box: 1419733141, Tehran, IR Iran. Tel/Fax: +98-2166945120, E-mail: azimicyrus@sina.tums.ac.ir

Received 2014 June 16; Revised 2014 August 4; Accepted 2014 August 28.

Abstract

Background: The incidence rate of gastric cancer in western countries has shown a remarkable decline in the recent years while it is still the most common cancer among males in Iran. The proto-oncogene *MYC*, located at 8q24.1, regulates almost 15% of human genes and is activated in 20% of all tumors. The amplification of *MYC* and overexpression of its protein product are observed in 15 - 30% of gastric neoplasias.

Objectives: The objective of this study was to find the preferences of Chromogenic In Situ Hybridization (CISH) and Immunohistochemistry (IHC) in diagnosis and prognosis of gastric cancer.

Patients and Methods: We studied 102 samples of gastric cancer in Iran and all the patients had undergone primary surgical resection at the Cancer Institute Hospital, Tehran University of Medical Sciences. The CISH and IHC techniques were applied for all our samples. All of the samples had adenocarcinoma gastric cancer and were selected randomly. Also, the type of study was cross sectional. The sample size was 100 patients.

Results: Our data revealed that both diffuse and intestinal types of gastric cancer occurred significantly more in males than females. Our results showed that there was an indication of some correlation between grades and CISH, although the difference was not significant. Our data also showed that CISH positive patients (43%) were more frequent compared to IHC positive patients (14.7%). There was a correlation between CISH and IHC. These results revealed that there was a significant difference between grades and IHC. There was also no statistical difference between CISH amplification in diffuse and intestinal types.

Conclusions: From the results, it could be concluded that for administration of the treatment of stomach cancer, and progress and prognosis of tumor, which is important for patients and clinicians, the CISH is a better and more feasible test than IHC, in regards to sensitivity and specificity.

Keywords: C-MYC, Chromogenic In Situ hybridization (CISH), Immunohistochemistry (IHC), Adenocarcinoma, Stomach

1. Background

Cancer is a leading cause of death worldwide and accounts for 7.6 million deaths every year. The first and second most common causes of cancer death in the world are lung cancer (1.37 million deaths, annually) and gastric cancer (736000 deaths, annually), respectively (1). About 70% of all cancer deaths have occurred in low- and middle-income countries. Gastric cancer is the fourth most common cancer in males, while in females it is the fifth most common cancer (based on statistics published in 2008) (2). The incidence rate of gastric cancer in western countries has shown a remarkable decline in the recent years while it is still the most common cancer among males in Iran. Based on Age-Standardized Incidence Rates (ASR) the most common cancer in males was stomach (10.2), while in

females, stomach cancer (5.1) was the third most common cancer (3). Although the incidence of stomach cancer is decreasing, it is still a major health problem and a major cause of cancer death around the world (4).

It has been suggested that carcinogenesis of stomach cancer is due to a collection of genetic alterations of many genes such as oncogenes, tumor suppressor, and mismatch repair genes (5). It has been suggested that there are many genes that raise the risk of stomach cancer, because some genes such as *MCC*, *APC*, and *P53* tumor suppressor genes have been found in a numerous cases of gastric cancers (6).

Cadherin-1, also known as CAM 120/80 or epithelial cadherin (E-cadherin), is a protein that in humans is encoded by the *CDH1* gene, which is a tumor suppressor

gene (7). Many researchers have reported E-cadherin, a calcium-dependent adhesion molecule that is responsible for cellular binding to adjacent cells, as an important part in the etiology of stomach carcinogenesis (8). Genetic predisposition implicates transmission of a single mutated *CDH1* allele. If a second similar allele has been in the E-cadherin gene, then lack of intracellular adhesion causes an increase in intracellular permeability (9). A broad range of mutations has been found in gastric cancers (10).

The frequency of stomach cancer is higher among senile populations, manifesting more at about 70 to 80 years of age. In a study with a large sample, the mean age of diagnosis was 67 years old (11). Worse clinicopathologic characteristics and prognosis for gastric cancer has been suggested among young patients (12). The proto-oncogene *MYC*, located at 8q24.1, encodes a nuclear phosphoprotein, regulates almost 15% of human genes and is activated in 20% of all tumors (13).

Activation of unsuitable *MYC* gene, which contributes to the development of human tumors, is functioned through different mechanisms: chromosome translocations, which has already been shown in Burkitt lymphoma; juxtaposition of the promoter region of the immunoglobulin heavy chain gene, which is highly expressed in B cells, because it is next to the *MYC* gene; excitation of gene transcription, as has been documented in colon cancer cells; retrovirus insertion next to the *MYC* locus, where through the retroviral regulatory sequences, the *MYC* expression would be activated, and gene amplification and the copy number of *MYC* gene would be excessed, and as a result its expression would be increased between other cells (14).

Hence, any changes in *MYC* oncogene are usually persuaded by phenomena such as gene amplification, chromosome translocation, point mutations, viral insertion at the *MYC* locus, and resistance of *MYC* protein to ubiquitin-mediated proteolysis and raised translation or transcription by signaling other oncogenic pathways (15).

The location of the *MYC* protein is in the nucleus, and acts as a growth promoter and a transcription factor. Transcription factors of bHLH are a big family, which contain *MYC*, and form homo and heterodimers with themselves and with other family members. These dimeric complexes are related to regulatory sequences called E-boxes (with CACGTG sequence), detected in promoters of target genes, which they regulate (16). One of the necessary ligands for most of biological functions is the MAX protein, which is used by *MYC*. When MAX and *MYC* proteins dimerize, they will act to activate transcription. Although it seems that the *MYC* protein is expressed independently, yet in fact, the *MYC* protein of each cell is complexed with the MAX protein (17).

Usually, the levels of MAX are stable within cells, yet the *MYC* levels are strongly affected by mitogenic signals. In this regard, when normal cells are grown

without mitogenic components, the level of *MYC* will fall, while, *MYC* accumulates significantly in the presence of serum mitogens. This indicates that the levels of *MYC*-MAX heterodimer are constantly regulated by the current of mitogenic signals, which normal cells receive (16). The *MYC* gene has three exons, and its protein products (p64 and p67) include strongly conserved nuclear phosphoproteins, with high amounts of p64 compared with p67, called *MYC*-2 and *MYC*-1, respectively (18).

It has been suggested that patients with late stages of gastric cancers or with metastases, show higher levels of *MYC* amplification, and on the contrary, patients at the early stages show lower amplification (19). The amplification of *MYC* and overexpression of its protein are found in 15 to 30% of gastric cancers (20). Some authors have suggested that *MYC* overexpression is more frequent than *MYC* gene amplification in stomach adenocarcinoma (21). In more than 40% of cases with stomach cancer, overexpression of *MYC* has been reported (22). Some researchers have reported on the association between metastasis and higher level of *MYC* expression (22). Another report showed that *MYC* mRNA levels were also higher in patients with metastasis than in cases with primary lesions (23). Yang et al. pointed out that in advanced stomach cancers, *MYC* expression was higher than in early stages (24). On the contrary, Onoda et al. suggested that *MYC* expression was more frequent in early than in advanced lesions, yet other studies have not proved this difference (23). Tsuboi et al. (19) noticed that *MYC* protein expression elevated gradually as the lesion progressed, such as that found in chronic active gastritis, gastric ulcer, mild non-classic proliferation, severe non-classic proliferation, and early and advanced stomach cancer (19). These findings proved that *MYC* amplification could be a serious phenomenon of gastric carcinogenesis.

2. Objectives

The objective of this study was to find the preferences of CISH and IHC in diagnosis and prognosis of gastric cancer among 102 patients with adenocarcinoma.

3. Patients and Methods

3.1. Clinical Specimens

This investigation included 102 Iranian patients with adenocarcinoma gastric cancer. The type of study was cross sectional. This study was done from year 2009 to 2014. Samples were gathered from 102 paraffin-embedded blocks, and also 50 blocks from adjacent normal stomach mucosa, as negative control samples. All patients had stomach surgery at the Cancer Institute Hospital, Tehran University of Medical Sciences. All patients had a negative history of exposure to either

chemotherapy or radiotherapy before surgery. Originally, the samples were 105 patients, yet three samples were excluded, because they received a new adjuvant therapy. The main objective of this study was to investigate the expression of *C-MYC* in patients with gastric cancer. More than 40% of stomach cancers show abundant expression of *MYC*, as indicated by previous reports. The sample size was calculated using the following formula:

$$(1) \quad n = \frac{z^2 p(1-p)}{d^2}$$

Considering that $Z = 1.96$, $P = 40\%$ and accuracy was 10%, 92 samples were sufficient for this study. To ensure a 10% increase, 100 samples were studied.

$$(2) \quad N = \frac{((1.96)^2 \times (0.4 \times 0.6))}{0.1^2} = 92.2$$

Patients and tissue samples: sample size for this study was calculated.

Patients' approval was retained according to local authorities by the Ethics Committee, Tumor Bank, Cancer Institute of Iran. Written informed consent was obtained from all participants and the Institutional Ethics Committee approved the study.

Gastric cancer samples were classified according to Lauren (25). The patients were staged using a standard method by Tumor-Nodes-Metastasis (TNM) staging (26).

3.2. Chromogenic In Situ Hybridization

Chromogenic in Situ Hybridization (CISH) was carried out on 3- μ m-thick formalin-fixed paraffin-embedded tissue sections. The 3- μ m-thick sections were cut from paraffin blocks and dewaxed with xylene, and then rehydrated with a series of 70% to 100% ethanol and water. Target retrieval and enzyme digestion were achieved using a commercially available tissue pretreatment kit (no.C-3018-40; from ZytoDot Germany). All denaturation and hybridization kits were made in China.

On the first day, slides were incubated in pretreatment buffer, in a water bath (mmert-Germany) to at least 85°C for 30 minutes, with a ZytoDot CISH Implementation Kit (Germany). Next, pepsin solution was applied to the tissue followed by incubation for eight minutes at room temperature in a humidity chamber. The sections were dehydrated in upgrading ethanol series and air-dried. Ten microliters of zytoDot CISH probe *C-MYC* were applied to the slides, and the slides were enclosed by a coverslip (22 x 22mm) and denatured on a hot plate for five minutes at 94 - 95 °C. The slides were then transferred to a humidity chamber and hybridized overnight at 37°C.

On the second day, the coverslip was removed by soak-

ing in Standard Saline Citrate (SSC) solution at room temperature for five to ten minutes and washed in SSC buffer for five minutes at 75°C. The slides were incubated in 3% H_2O_2 for 10 minutes. Blocking solution was also applied to the slides. Next, a hybridized probe linked to digoxigenin was detected by mouse anti-digoxigenin antibody followed by polymerized horseradish peroxidase anti-mouse immunoglobulin. Peroxidase was developed with diaminobenzidine, and nuclei were counterstained with hematoxylin. All detection reagents were provided by commercially available kits.

The interpretation of CISH results was performed by the first author (M.Kh) with a light microscope using a 40 \times objective (original magnification, 100 \times ; Figure 1 A - D). Signals were seen as nuclear dark brown dots. Fifty to 100 non-overlapping tumor cell nuclei were evaluated per sample. A gene copy number of one to two copies per nucleus were scored as "no amplification" (Figure 1A). A gene copy number of two to four copies per nucleus in at least 50% of cancer cells were considered as "low-level amplification" (Figure 1B). A gene copy number of four to six copies per nucleus in at least 50% of cancer cells were considered as "moderate level amplification" (Figure 1C). A gene copy number of more than six copies per nucleus or the presence of clusters in at least 50% of cancer cells was considered as "high-level amplification" (Figure 1D) (18, 19, 27). Non-neoplastic cells in tissues were always considered as in-test quality controls. Chromogenic in situ hybridization were evaluated with Leitz microscope images and were captured with a digital Nikon camera. All the slides of patients were confirmed for diagnosis and were checked for CISH and IHC by one senior pathologist (I.J).

3.3. Immunohistochemistry

Immunohistochemical staining was performed according to Calcagno *et al.* (28). The 3- μ m-thick sections were cut and deparaffinized. Slides were incubated in hydrogen peroxide, and antigen retrieval was carried out by heat treatment in 0.294% wt/vol citrate buffer at pH 6.0 in a domestic microwave oven (botan-Iran) as follows: 900 W for five minutes and then 600 W for 10 minutes, excluding slides that were dried out. Tissues were incubated in digestive enzyme (pepsin enzyme), for five minutes. Super Block was then applied. Immunohistochemical staining was performed using the Horse-Radish Peroxidase (HRP) method with a monoclonal antibody (monoclonal rabbit, Ready to use, PME 415 AA Biocare Medical, USA), as recommended by the manufacturer. A universal peroxidase-conjugated secondary antibody kit (AmpliStain Anti-Mouse/Rabbit 1-Step HRP, Germany) was used for the detection system (SDT, Germany). The slides were visualized with diaminobenzidine- H_2O_2 (DAB) and counterstained with hematoxylin (SDT). Any nuclear stain with or without cytoplasmic staining was considered as positive results,

irrespective of intensity (Figure 2). A MYC-positive case was defined as one having 10% or more tumor cells positive for this protein.

3.4. Data analysis


The statistical calculation was carried out using version 18 of the SPSS software for Windows. In order to assess the degree of agreement between CISH and IHC test, Kappa statistics was applied. The variables of patients according to the two types of diffuse and intestinal gastric cancers were analyzed using the chi-square test. The variables of patients according to *C-MYC* amplification (CISH) and *C-MYC* expression (IHC) with two groups were tested with the Mann-Whitney test, and variables with more than two groups were tested with Kruskal-Wallis. For determining

the association between CISH and IHC, Kappa test and the Spearman correlation coefficient were used. Commentary of the Kappa test was as follows: poor agreement (less than 0.20), fair agreement (0.20 to 0.40), moderate agreement (0.40 to 0.60), good agreement (0.60 to 0.80), and very good agreement (0.80 to 1.00) (29). P values of less than 0.05 were considered as significant in all tests.

4. Results

This investigation included 102 patients from Iran with gastric adenocarcinomas. In our samples, 78 patients were males and 24 cases were females, and the average age was 60.62 years old. The amplification of *MYC* and its protein expression (CISH and IHC tests) were carried out and analyzed for all patients.

Figure 1. The Results of *MYC* Amplification by Chromogenic In Situ Hybridization Test



A, No amplification; B, Low amplification (2 - 4 signals); C, Moderate amplification (4 - 6 signals); D, High amplification (more than six signals, which looked as large copy gene clusters in the majority of the nuclei of gastric cancer cells) (original magnification, 500 ×).

4.1. Clinical Results

The clinicopathological features are shown in Table 1. The location of the tumor was the fundus in 35.3% of patients, while the location was the cardia in only 3%. Types of gastric cancers were diffuse (56.9%) or intestinal (43.1%). The average tumor size of patients was 6.49 cm. Table 1 shows that some of the variables including gender, location of tumor, necrosis, vascular invasion, perineural invasion, CISH, and IHC had significant differences amongst the diffuse type, while gender, location of tumor, vascular invasion, necrosis, CISH, and IHC had significant differences amongst the intestinal type. This means that subgroups of each variable are different in the two types of gastric cancer. These results also showed that there was no relationship between age, grade and stage, and type of stomach cancer. Our data revealed that both diffuse and intestinal types of gastric cancer occurred significantly more in males than females (Table 1). The majority of our patients (69.6%) were in grades II and III, which was the same as the stages, with 59.8% in stages II and III (Table 1).

4.2. Chromogenic In Situ Hybridization (CISH) Results


The results of CISH and IHC are shown in Table 1. This study revealed that there was no association between age, gender, tumor location, necrosis, vascular invasion, perineural invasion, stages and type of gastric cancer, and the CISH test. Our data showed that there was an indication of some correlation between grades and CISH, although the difference was not significant. Our data also showed that CISH+ patients (43.1%) were more frequent compared to IHC+ patients (14.7%). Table 3 shows the correlation be-

tween CISH and IHC. Different amplifications by the CISH test are shown in Table 2. According to our CISH data, 58 samples showed no amplification and among 44 samples with CISH+, 24 samples showed low amplification. Six samples showed moderate amplification and 14 samples showed high amplification. We also considered low amplification as CISH+ (Table 3).

4.3. Immunohistochemistry (IHC) Results

Table 2 shows the comparison of CISH and IHC. This result revealed that there was a significant difference between grades and IHC. Table 3 shows the results of IHC positive and negative patients. Immunoreactivity of *MYC* was seen in 15 patients. In 13 patients both *MYC* amplification and *MYC* immunoreactivity were observed. Fifty-six samples had no amplification and were IHC negative. Also among 44 positive samples for CISH, 13 samples had positive signals for IHC and 31 samples had negative signals for IHC. Most of the IHC negative patients had no amplification yet only two IHC positive patients had no amplification. Normal cells also had IHC negative results (Table 3). Our patients were divided to four groups. The first group was both CISH+ and IHC+ (12.7%). The second was CISH+ and IHC- (30.3%). The third group was CISH- and IHC+ (2%). The fourth group was CISH- and IHC- (55%). Amongst our four groups, the kappa test result was 0.284, which indicated fair agreement between CISH and IHC (Table 3). To determine the association between CISH and IHC testing, the Spearman correlation coefficient was applied. The correlation coefficient was -0.365 with a p value of 0.0001, indicating that these two tests were related. In this investigation 43% of the samples were positive for CISH, yet only 14.7% were positive for IHC.

Figure 2. The Results of C-MYC Expression by the Immunohistochemistry Test



A, Negative IHC in gastric adenocarcinoma; B, Positive IHC in gastric adenocarcinoma.

Table 1. Clinical and Laboratory Results of Patients According to the Two Types of Diffuse and Intestinal Gastric Caners

Variable	Type of Gastric Caners			
	Diffuse		Intestinal	
	No. (%)	P Value	No. (%)	P Value
Age, y				0.132
< 60	28 (48.3)	0.793	17 (38.6)	
> 60	30 (51.7)		27 (61.4)	
Gender		0.000		0.000
Male	44 (75.9)		34 (77.3)	
Female	14 (24.1)		10 (22.7)	
Location of Tumor		0.0001		0.009
Fundus	25 (43.1)		11 (25)	
Pylorus	3 (5.2)		2 (4.5)	
Esophagus	6 (10.3)		3 (6.8)	
Cardia	2 (3.4)		1 (2.3)	
Lesser curvature	5 (8.6)		8 (18.2)	
Corpus-body	11 (19)		8 (18.2)	
Antrum	5 (8.6)		11 (25)	
Missing	1 (1.7)		-	
Grade		0.319		0.110
I	16 (27.6)		13 (29.5)	
II	16 (27.6)		21 (47.7)	
III	24 (41.4)		10 (22.7)	
Missing	2 (3.4)		-	
Necrosis		0.002		0.002
Yes	13 (22.4)		6 (13.6)	
No	9 (15.5)		11 (25)	
N/A	28 (48.3)		24 (54.4)	
Missing	8 (13.8)		3 (6.8)	
Vascular invasion		0.001		0.001
Yes	48 (82.8)		30 (68.2)	
No	6 (10.3)		13 (29.5)	
Missing	4 (6.9)		1 (2.3)	
Perineural invasion		0.002		0.446
Yes	39 (67.2)		24 (54.5)	
No	16 (27.6)		19 (43.2)	
Missing	3 (5.2)		1 (2.3)	
Stage		0.313		0.651
I	13 (22.4)		9 (20.5)	
II	18 (31)		14 (31.8)	
III	17 (29.3)		12 (27.3)	
IV	9 (15.5)		9 (20.5)	
Missing	1 (1.7)		0 (0)	
CISH Amplification				
< 2 Signals	32 (55.2)	0.0001	26 (59.1)	0.0001
2 - 4 Signals	14 (24.1)		10 (22.7)	
4 - 6 Signals	4 (6.9)		2 (4.5)	
(> 6 Signals)	8 (13.8)		6 (13.6)	
IHC		0.0001		0.0001
Positive	11 (19)		4 (9.1)	
Negative	47 (81)		40 (90.9)	

Table 2. Clinical and Laboratory Results of Patients According to C-MYC Amplification (CISH) and C-MYC Expression (IHC)

Variable	IHC			CISH			
	Positive (n = 15) No. (%)	Negative (n = 87) No. (%)	No (n = 58) No. (%)	Low (n = 24) No. (%)	Moderate (n = 6) No. (%)	High (n = 14) No. (%)	sig
Age, y							0.830
< 60	7 (46.7)	38 (43.7)	27 (46.6)	12 (50)	3 (50)	3 (21.4)	
> 60	8 (53.3)	49 (56.3)	31 (53.4)	12 (50)	3 (50)	11 (78.6)	
Gender							0.728
Male	12 (80)	38 (43.7)	43 (74.1)	17 (70.8)	6 (100)	12 (85.7)	
Female	3 (20)	49 (56.3)	15 (25.9)	7 (29.2)	0 (0)	2 (14.3)	
Location							0.824
Fundus	7 (46.7)	29 (33.3)	14 (24.1)	13 (54.2)	3 (50)	6 (42.9)	
Pylorus	1 (6.7)	4 (4.6)	3 (5.2)	0 (0)	1 (16.7)	1 (7.1)	
Esophagus	1 (6.7)	8 (9.2)	7 (12.1)	0 (0)	0 (0)	2 (14.3)	
Cardia	0 (0)	3 (3.4)	2 (3.4)	0 (0)	0 (0)	1 (7.1)	
Lesser Curvature	2 (13.3)	11 (12.6)	7 (12.1)	4 (16.7)	1 (16.7)	1 (7.1)	
Corpus-body	1 (6.7)	18 (20.7)	14 (24.1)	3 (12.5)	1 (16.7)	1 (7.1)	
Antrum	3 (20)	13 (14.9)	10 (17.2)	4 (16.7)	0 (0)	2 (14.3)	
Missing	-	1 (1.1)	1 (1.7)	0 (0)	0 (0)	0 (0)	
Grade							0.002
I	1 (6.7)	28 (32.2)	20 (34.5)	7 (29.2)	0 (0)	2 (14.3)	
II	3 (20)	34 (39.1)	22 (37.9)	9 (37.5)	2 (33.3)	4 (28.6)	
III	11 (73.3)	23 (26.4)	15 (25.9)	8 (33.3)	4 (66.7)	7 (50)	
Missing	-	2 (2.3)	1 (1.7)	0 (0)	0 (0)	1 (7.1)	
Necrose							0.790
Yes	3 (20)	16 (18.4)	14 (24.1)	2 (8.3)	2 (33.3)	1 (7.1)	
No	4 (26.7)	16 (18.4)	9 (15.5)	5 (20.8)	2 (33.3)	4 (28.6)	
N/A	7 (46.7)	45 (51.7)	31 (53.4)	14 (58.3)	2 (33.3)	5 (35.7)	
Missing	1 (6.7)	10 (11.5)	4 (6.9)	3 (12.5)	0 (0)	4 (28.6)	
Vascular invasion							0.248
Yes	12 (80)	66 (75.9)	43 (74.1)	19 (79.2)	4 (66.7)	12 (85.7)	
No	1 (6.7)	18 (20.7)	13 (22.4)	4 (16.7)	1 (16.7)	1 (7.1)	
Missing	2 (13.3)	3 (3.4)	2 (3.4)	1 (4.2)	1 (16.7)	1 (7.1)	
Perineural invasion							0.072
Yes	12 (80)	51 (58.6)	33 (56.9)	15 (62.5)	5 (83.3)	10 (71.4)	
No	2 (13.3)	33 (37.9)	23 (39.7)	8 (33.3)	1 (16.7)	3 (21.4)	
Missing	1 (6.7)	3 (3.4)	2 (3.4)	1 (4.2)	0 (0)	1 (7.1)	
Stage							0.252
I	4 (26.7)	18 (20.7)	15 (25.9)	5 (20.8)	0 (0)	2 (14.3)	
II	5 (33.3)	27 (31)	18 (31)	6 (25)	3 (50)	5 (35.7)	
III	6 (40)	23 (26.4)	17 (29.3)	6 (25)	2 (33.3)	4 (28.6)	
IV	0 (0)	18 (20.7)	8 (13.8)	6 (25)	1 (16.7)	3 (21.4)	
Missing	0 (0)	1 (1.1)	0 (0)	1 (4.2)	0 (0)	0 (0)	
Type							0.165
Diffuse	11 (73.3)	47 (54)	32 (55.2)	14 (58.3)	4 (66.7)	8 (57.1)	
Intestinal	4 (26.7)	40 (46)	26 (44.8)	10 (41.7)	2 (33.3)	6 (42.9)	

Table 3. The Results of the Correlation Between *C-MYC* Amplification and *C-MYC* Expression Among 102 Patients With Stomach Cancers^{a,b}

IHC	CISH		Total
	Positive	Negative	
Positive	13 (12.7)	2 (2)	15 (14.7)
Negative	31 (30.4)	56 (55)	87 (85.3)
Total	44 (43.1)	58 (57)	102 (100)

^aKappa: value agreement = 0.284, percentage of agreement = 28.4%, P value = 0.0001, statistically significant difference from zero.

^bThe values are presented as No. (%).

5. Discussion

In the present investigation, 102 patients with stomach cancer were assessed. Our cases included of 78 males and 24 females, with a male: female ratio of nearly 3:1, and an average age of 60, 62. Our data were in agreement with another research, which gave a ratio of 2:1 and the majority of the patients were older than fifty-five (30). Another study from Iran was also in agreement with our results and mentioned that gastric cancer was the most common cancer in Iranian males (31).

In this study, the tumor location was divided into seven subgroups and the majority of our patients had a tumor in the fundus location. If we divided our patients into two groups of cardia and non-cardia, we would have only 3% cardia and 97% non-cardia. One research studied gastric cancer among 125 samples, with only two subgroups of cardia and non-cardia, and found that 58.4% of the samples were in the non-cardia subgroup, which is in agreement with our results (30).

The majority (59.9%) of our patients had the diffuse type, yet some authors reported intestinal type more than the diffuse type (30-32). The best explanation for this difference is that their samples were from Brazil and Japan, both being high-risk areas, yet our data was from Tehran, which is considered a low-risk area. It has been already documented that intestinal type of gastric adenocarcinoma was more frequent than the diffuse type in high-risk countries (33).

Some authors have reported an association between overexpression of *C-MYC* and over 50% of cancers in humans, and also the effect of this overexpression on invasiveness and worse prognosis in patients. Contribution of *MYC* to tumorigenesis by persuading reless cellular growth, angiogenesis, proliferation, and genomic instability has been already documented (34). It was suggested that the *C-MYC* constitutive expression owing to amplification, mutation, or chromosome translocation involves the development and progression of various cancers (35). *C-MYC* persuades point mutations, imperfect replication initiation, DNA breakage, changes of DNA repair, and causes remodeling of the 3D nuclear structure of telomeres and chromosomes, thus leading to topological positions that initiate genomic instability (36).

Most of the patients in different studies were at the ear-

ly stage of gastric cancer and from high-risk areas, such as Japan and Korea. However, another author showed higher *MYC* amplification in the diffuse-type, than the intestinal-type, which agreed with our results (28). One study of IHC analysis revealed that *MYC* expression was more frequent in the intestinal-type than the diffuse-type (37). On the contrary, we observed more frequent *MYC* expression in the diffuse type.

Association of *MYC* over-expression with the proliferative phases of cells has been documented and this expression was shown only in proliferative phases of development, but not in quiescent or terminally differentiated cells (38). Our results revealed that there was a significant difference between grades and IHC. We showed an increase in *MYC* expression, especially in grades II and III. This result is similar to the findings of previous results, which revealed that *MYC* expression is down regulated with cell differentiation, and also another investigation, which showed the *MYC* expression was repressed in grade I gastric cancers, whereas there was a significant increase of *MYC* protein expression in grades II and III (38). In our investigation there was no significant difference between IHC and stage. However, some studies have shown high levels of *MYC* protein expression at early stages (39). There was no significant difference in the percentage of cells with *C-MYC* gene amplification between early (pT1) and advanced (pT2-4) stomach cancers (39). This study was in agreement with our investigation.

It was suggested that there was no association between *C-MYC* gene amplification and differentiated/undifferentiated carcinomas (39). However, our data showed that there was an indication of some correlation between CISH and grades, although the difference was not significant.

The range of *MYC* overexpression was reported from 15.6% to 100% at the early stages of stomach cancer (40). However, in our study only 14.7% showed *MYC* immunoreactivity (IHC+) in both types, and 85.3% had no expression. This level was less than previous studies (30). The probable reason is that all of our patients were randomly selected from different stages. The most usual mechanism of deregulation of *MYC* in stomach cancer is *MYC* amplification (41). This mechanism leads to enhanced

oncogenic products in quantities that exceed the transcriptional capacity (42). In this regard, we also observed three or more *MYC* gene copies (dots) in 43% of gastric tumors among our patients. However, in previous studies, all of the samples showed amplification. Therefore, this investigation was not in agreement with previous studies (27, 28, 43). The probable cause would be that all of our samples were from different stages (mostly late stage), yet in the previous two studies, the samples were only from early stages. Our study also showed that amplification of *C-MYC* in the diffuse type was more frequent than in the intestinal type, which was not in accordance with some previous reports (28, 43). Also our study revealed no correlation between age, gender, tumor location, necrosis, vascular invasion, perineural invasion and type of gastric cancer, and CISH test. One study from China revealed that any relationship between *MYC* amplification and clinicopathological characteristics (grade, stage, lymph node metastasis, tumor location) in gastric cancer is correlated with ethnicity (44). "However, due to the fact that our study could not find any relationship between *MYC* amplification and clinicopathological characteristics, it is possible to report that the ethnicity of Iranian patients afflicted, might lead to no relationship between these two parameters."

Among our samples 12.7% had both positive CISH and IHC. Although we observed *C-MYC* amplification (CISH-) and IHC+ in only two patients, it seems that this may have been an artifact. Overall, 30.3% of our patients showed *C-MYC* amplification (CISH+), yet the protein was not expressed (IHC-) (Table 3). The possible explanation would be that a mechanism might have degraded the protein or the mRNA (45). Our data showed a correlation between CISH and IHC, and the percentage of positive CISH and IHC were 43% and 14.7%, respectively. Therefore, it might be concluded that CISH is a better test than IHC.

Some authors discussed on the molecular therapeutic targeting of *MYC* and showed that *MYC* inactivation suppresses tumors in animals (37). In other words, specific knockdown of *C-MYC* may decrease the growth and proliferation of gastric cancer cells, therefore, *C-MYC* could be a possible target in gene therapy (46).

Acknowledgments

Dr. Cyrus Azimi and Ms. Malihea Khaleghian would like to thank the Cancer Research Center, Tehran University of Medical Sciences, for their kind financial support (Grant number: 90-01-51-13605). This manuscript was extracted from Ms Khaleghian's Ph.D. thesis submitted to the Tehran University of Medical Sciences.

Footnotes

Authors' Contribution: Malihea Khaleghian and Issa Jahanzad have equal contributions to this work. Study concept and design: Abbas Shakoori, Malihea Khaleghian, and Cyrus Azimi; acquisition of data: Malihea Khaleghian

and Issa Jahanzad; analysis and interpretation of data: Issa Jahanzad and Malihea Khaleghian; drafting of the manuscript: Cyrus Azimi and Malihea Khaleghian; critical revision of the manuscript for important intellectual content: Cyrus Azimi and Malihea Khaleghian; statistical analysis: Amirnader Emami Razavi and Maryam Mohammadi; administrative, technical, and material support: Malihea Khaleghian, Issa Jahanzad, and Abbas Shakoori; study supervision: Cyrus Azimi.

Funding/Support: This study was carried out mainly by personal funds, and partially funded and supported by a grant awarded to Dr. Cyrus Azimi and supported by a grant awarded to Dr. Cyrus Azimi and Ms. Malihea Khaleghian from the Cancer Research Center, Tehran University of Medical Sciences, (Grant number: 90-01-51-13605), for Ms. Khaleghian's Ph.D. project.

References

1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. *Int J Cancer*. 2013;**132**(5):1133-45. doi:10.1002/ijc.27711. [PubMed: 22752881]
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin*. 2005;**55**(2):74-108. [PubMed: 15761078]
3. Derakhshan MH, Yazdanbod A, Sadjadi AR, Shokoobi B, McColl KE, Malekzadeh R. High incidence of adenocarcinoma arising from the right side of the gastric cardia in NW Iran. *Gut*. 2004;**53**(9):1262-6. doi: 10.1136/gut.2003.035857. [PubMed: 15306582]
4. Fan XM, Wong BC, Wang WP, Zhou XM, Cho CH, Yuen ST, et al. Inhibition of proteasome function induced apoptosis in gastric cancer. *Int J Cancer*. 2001;**93**(4):481-8. [PubMed: 11477551]
5. Holian O, Wahid S, Atten MJ, Attar BM. Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. *Am J Physiol Gastrointest Liver Physiol*. 2002;**282**(5):G809-16. doi: 10.1152/ajpgi.00193.2001. [PubMed: 11960777]
6. Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. *Gastroenterology*. 1994;**106**(6):1584-8. [PubMed: 8194705]
7. Wong AS, Gumbiner BM. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. *J Cell Biol*. 2003;**161**(6):1191-203. doi: 10.1083/jcb.200212033. [PubMed: 12810698]
8. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. *J Med Genet*. 2004;**41**(7):508-17. [PubMed: 15235021]
9. Robertson EV, Jankowski JA. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. *Am J Gastroenterol*. 2008;**103**(2):443-9. doi: 10.1111/j.1572-0241.2007.01574.x. [PubMed: 17925001]
10. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. *Int J Surg Pathol*. 2006;**14**(1):21-33. [PubMed: 16501831]
11. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. *Cancer*. 2000;**88**(4):921-32. [PubMed: 10679663]
12. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Choi WH, et al. Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. *Ann Surg Oncol*. 2008;**15**(5):1464-9. doi: 10.1245/s10434-008-9809-1. [PubMed: 18340495]
13. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. *Semin Cancer Biol*. 2006;**16**(4):253-64.

- doi: 10.1016/j.semcancer.2006.07.014. [PubMed: 16904903]
14. Ryan KM, Birnie GD. Myc oncogenes: the enigmatic family. *Biochem J*. 1996;**314** (Pt 3):713-21. [PubMed: 8615760]
 15. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. *Semin Cancer Biol*. 2006;**16**(4):318-30. doi: 10.1016/j.semcancer.2006.07.015. [PubMed: 16934487]
 16. Weinberg RA. *A biologia do câncer*. 1st ed. Brazil: Porto Alegre; 2008.
 17. Diolaiti D, McFerrin L, Carroll PA, Eisenman RN. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. *Biochim Biophys Acta*. 2015;**1849**(5):484-500. doi: 10.1016/j.bbagr.2014.05.016. [PubMed: 24857747]
 18. Bizari L, Silva AE, Tajara EH. Gene amplification in carcinogenesis. *Genetics Molecular Biology*. 2006;**29**(1):1-7.
 19. Tsuboi K, Hirayoshi K, Takeuchi K, Sabe H, Shimada Y, Ohshio G, et al. Expression of the c-myc gene in human gastrointestinal malignancies. *Biochem Biophys Res Commun*. 1987;**146**(2):699-704. [PubMed: 3619899]
 20. Matsui A, Ihara T, Suda H, Mikami H, Semba K. Gene amplification: mechanisms and involvement in cancer. *Biomol Concepts*. 2013;**4**(6):567-82. doi: 10.1515/bmc-2013-0026. [PubMed: 25436757]
 21. Shon W, Sukov WR, Jenkins SM, Folpe AL. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study. *Mod Pathol*. 2014;**27**(4):509-15. doi: 10.1038/modpathol.2013.163. [PubMed: 24091875]
 22. Milne AN, Sitarz R, Carvalho R, Carneiro F, Offerhaus GJ. Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. *Curr Mol Med*. 2007;**7**(1):15-28. [PubMed: 17311530]
 23. Onoda N, Maeda K, Chung YS, Yano Y, Matsui-Yuasa I, Otani S, et al. Overexpression of c-myc messenger RNA in primary and metastatic lesions of carcinoma of the stomach. *J Am Coll Surg*. 1996;**182**(1):55-9. [PubMed: 8542090]
 24. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC, Luo J. Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: association with Helicobacter pylori cagA(+) infection. *World J Gastroenterology*. 2004;**10**(4):491-6. doi: 10.3748/wjg.v10.i4.491.
 25. Owens SR, Appelman HD. *Carcinoma of the Stomach. Atlas of Esophagus and Stomach Pathology*. 1st ed. New York: Springer; 2014.
 26. Sobin LH, Gospodarowicz MK, Wittekind C. *TNM classification of malignant tumours*. 1st ed. New Jersey: John Wiley & Sons; 2011.
 27. Shah MA, Ajani JA. Gastric cancer—an enigmatic and heterogeneous disease. *JAMA*. 2010;**303**(17):1753-4. doi: 10.1001/jama.2010.553. [PubMed: 20442394]
 28. Calcagno DQ, Guimaraes AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, et al. MYC insertions in diffuse-type gastric adenocarcinoma. *Anticancer Res*. 2009;**29**(7):2479-83. [PubMed: 19596917]
 29. Altman DG. *Practical statistics for medical research*. 1st ed. Florida: CRC Press; 1990.
 30. de Souza CR, Leal MF, Calcagno DQ, Costa Sozinho EK, Borges Bdo N, Montenegro RC, et al. MYC deregulation in gastric cancer and its clinicopathological implications. *PLoS One*. 2013;**8**(5):e64420. doi: 10.1371/journal.pone.0064420. [PubMed: 23717612]
 31. Sadjadi AR, Zahedi MJ, Nouraei M, Alimohammadian M, Ghorbani A, Bahmanyar S, et al. The first population-based cancer survey in Kerman Province of Iran. *Iran J Public Health*. 2007;**36**(4):26-34.
 32. Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. *Clin Cancer Res*. 2006;**12**(10):2995-3002. doi: 10.1158/1078-0432.CCR-05-1601. [PubMed: 16707594]
 33. Hamilton SR, Aaltonen LA. *Pathology and genetics of tumours of the digestive system*. 1st ed. Lyon: IARC Press; 2000.
 34. Arvanitis C, Felsner DW. Conditionally MYC: insights from novel transgenic models. *Cancer Lett*. 2005;**226**(2):95-9. doi: 10.1016/j.canlet.2004.10.043. [PubMed: 16039948]
 35. Louis SF, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztejn Z, et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. *Proc Natl Acad Sci U S A*. 2005;**102**(27):9613-8. doi: 10.1073/pnas.0407512102. [PubMed: 15983382]
 36. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. *Nat Rev Mol Cell Biol*. 2005;**6**(8):635-45. doi: 10.1038/nrnm1703. [PubMed: 16064138]
 37. Calcagno DQ, Freitas VM, Leal MF, de Souza CR, Demachki S, Montenegro R, et al. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. *BMC Gastroenterol*. 2013;**13**:141. doi: 10.1186/1471-230X-13-141. [PubMed: 24053468]
 38. Han S, Kim HY, Park K, Cho HJ, Lee MS, Kim HJ, et al. c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. *J Korean Med Sci*. 1999;**14**(5):526-30. [PubMed: 10576148]
 39. Suzuki S, Tenjin T, Watanabe H, Matsushima S, Shibuya T, Tanaka S. Low level c-myc gene amplification in gastric cancer detected by dual color fluorescence in situ hybridization analysis. *J Surg Oncol*. 1997;**66**(3):173-8. [PubMed: 9369962]
 40. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. *World J Gastroenterol*. 2008;**14**(39):5962-8. [PubMed: 18932273]
 41. Meyer N, Penn LZ. Reflecting on 25 years with MYC. *Nat Rev Cancer*. 2008;**8**(12):976-90. doi: 10.1038/nrc2231. [PubMed: 19029958]
 42. Calcagno DQ, Leal MF, Taken SS, Assumpcao PP, Demachki S, Smith Mde A, et al. Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. *Anticancer Res*. 2005;**25**(6B):4069-74. [PubMed: 16309200]
 43. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, et al. Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. *World J Gastroenterol*. 2006;**12**(38):6207-11. [PubMed: 17036397]
 44. Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y. The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. *PLoS One*. 2011;**6**(12):e29670. doi: 10.1371/journal.pone.0029670. [PubMed: 21712999]
 45. Shan Z, Shakoobi A, Bodaghi S, Goldsmith P, Jin J, Wiest JS. TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo. *PLoS One*. 2013;**8**(6):e66114. doi: 10.1371/journal.pone.0066114. [PubMed: 23776618]
 46. Zhang L, Hou Y, Ashktorab H, Gao L, Xu Y, Wu K, et al. The impact of C-MYC gene expression on gastric cancer cell. *Mol Cell Biochem*. 2010;**344**(1-2):125-35. doi: 10.1007/s11010-010-0536-0. [PubMed: 20737197]